April 21 (Reuters) - Gilead Sciences Inc GILD.O:
TRODELVY® PLUS KEYTRUDA® DEMONSTRATES A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER
GILEAD: POSITIVE TOPLINE RESULTS FROM PHASE 3 ASCENT-04/KEYNOTE-D19 STUDY
GILEAD: STUDY SHOWED SUPERIORITY OF TRODELVY PLUS KEYTRUDA VERSUS STANDARD OF CARE $(SOC)$ IN 1L METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
GILEAD: STUDY MET MAIN GOAL, WITH STATISTICALLY SIGNIFICANT,CLINICALLY MEANINGFUL IMPROVEMENT IN PFS
GILEAD: OVERALL SURVIVAL $(OS)$, KEY SECONDARY ENDPOINT, WASN'T MATURE AT TIME OF PFS PRIMARY ANALYSIS
GILEAD: TRODELVY PLUS KEYTRUDA SHOWS EARLY TREND IN IMPROVEMENT FOR OS VERSUS SOC IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1+ (CPS ≥10) MTNBC
GILEAD: WILL CONTINUE TO MONITOR OS OUTCOMES
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.